News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Nicholas Piramal India Limited Enters Into Pact With AstraZeneca
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MUMBAI -(Dow Jones)- Nicholas Piramal India Ltd. (500302.BY) Wednesday said it has signed a pact with AstraZeneca AB (AZN) of Sweden to develop pharmaceutical products.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
C-suite
BioNTech Founders To Leave Famed mRNA Biotech for New Venture
March 10, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
March 10, 2026
·
3 min read
·
Nick Paul Taylor
Funding
AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs
March 10, 2026
·
2 min read
·
Tristan Manalac
GLP-1s
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
March 9, 2026
·
2 min read
·
Nick Paul Taylor
